

Lise Estcourt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9245085/publications.pdf>

Version: 2024-02-01

144
papers

7,981
citations

159525

30
h-index

58549

82
g-index

165
all docs

165
docs citations

165
times ranked

10954
citing authors

#	ARTICLE	IF	CITATIONS
1	International Forum on Policies and Practice for Transfusion of <scp>ABO</scp> and <scp>RhD</scp> Nonâ€identical Platelets: Responses. Vox Sanguinis, 2022, 117, .	0.7	0
2	Methodological challenges for living systematic reviews conducted during the COVID-19 pandemic: A concept paper. Journal of Clinical Epidemiology, 2022, 141, 82-89.	2.4	24
3	The Difference in Potential Harms between Whole Blood and Component Blood Transfusion in major Bleeding: A Rapid Systematic Review and Meta-Analysis of RCTs. Transfusion Medicine Reviews, 2022, 36, 7-15.	0.9	14
4	Effect of Antiplatelet Therapy on Survival and Organ Supportâ€Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1247.	3.8	83
5	Convalescent Plasma for Covid-19 â€ Making Sense of the Inconsistencies. New England Journal of Medicine, 2022, 386, 1753-1754.	13.9	22
6	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. The Cochrane Library, 2022, 2022, .	1.5	20
7	Pharmacological interventions for the treatment of bleeding in people treated for blunt force or penetrating injury in an emergency department: a systematic review and network meta-analysis. The Cochrane Library, 2022, 2022, .	1.5	2
8	Assessing the risks of haemolysis as an adverse reaction following the transfusion of ABO incompatible plasma-containing components - A scoping review. Blood Reviews, 2022, 56, 100989.	2.8	9
9	Clinical use of Convalescent Plasma in the COVIDâ€19 pandemic: a transfusionâ€focussed gap analysis with recommendations for future research priorities. Vox Sanguinis, 2021, 116, 88-98.	0.7	30
10	Patient blood management interventions do not lead to important clinical benefits or cost-effectiveness for major surgery: a network meta-analysis. British Journal of Anaesthesia, 2021, 126, 149-156.	1.5	50
11	How should we use convalescent plasma therapies for the management of COVID-19?. Blood, 2021, 137, 1573-1581.	0.6	29
12	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 384, 1491-1502.	13.9	1,419
13	Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection. Journal of Infectious Diseases, 2021, 224, 595-605.	1.9	20
14	International Forum on the Collection and Use of COVIDâ€19 Convalescent Plasma: Responses. Vox Sanguinis, 2021, 116, e71-e120.	0.7	3
15	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Medicine, 2021, 47, 867-886.	3.9	65
16	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	13.9	778
17	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	3.8	498
18	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 777-789.	13.9	712

#	ARTICLE	IF	CITATIONS
19	Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. The Cochrane Library, 2021, 2021, CD013365.	1.5	18
20	Hyperimmune immunoglobulin for people with COVID-19. The Cochrane Library, 2021, 2021, .	1.5	0
21	Effect of Convalescent Plasma on Organ Support – Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1690.	3.8	169
22	Passive immune therapies: another tool against COVID-19. Hematology American Society of Hematology Education Program, 2021, 2021, 628-641.	0.9	9
23	Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia. The Cochrane Library, 2020, 2020, CD011771.	1.5	8
24	A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. The Cochrane Library, 2020, 2020, CD010981.	1.5	26
25	Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review. The Cochrane Library, 2020, 2020, CD012055.	1.5	10
26	Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. The Cochrane Library, 2020, 2020, .	1.5	21
27	National comparative audit of blood transfusion: 2014 audit of transfusion services and practice in children and adults with sickle cell disease. Transfusion Medicine, 2020, 30, 186-195.	0.5	3
28	Platelet transfusion: Alloimmunization and refractoriness. Seminars in Hematology, 2020, 57, 92-99.	1.8	14
29	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. The Cochrane Library, 2020, 10, CD013600.	1.5	91
30	Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials. Critical Care, 2020, 24, 449.	2.5	16
31	Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. The Cochrane Library, 2020, 2020, CD003146.	1.5	11
32	Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. The Cochrane Library, 2020, 2020, CD012022.	1.5	23
33	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1317.	3.8	671
34	Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and network meta-analysis. The Cochrane Library, 2020, , .	1.5	1
35	Convalescent plasma for covid-19. BMJ, The, 2020, 370, m3516.	3.0	27
36	The haemoglobinopathy survey: The reality of transfusion practice in sickle cell disease and thalassaemia in England. Transfusion Medicine, 2020, 30, 456-466.	0.5	4

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of chemical thromboprophylaxis in renal transplantation – A systematic review. <i>Thrombosis Research</i> , 2020, 192, 88-95.	0.8	4
38	Preoperative blood transfusions for sickle cell disease. <i>The Cochrane Library</i> , 2020, 7, CD003149.	1.5	3
39	International Survey of Trials of Convalescent Plasma to Treat COVID-19 Infection. <i>Transfusion Medicine Reviews</i> , 2020, 34, 151-157.	0.9	28
40	British Society of Gastroenterology (BSG)-led multisociety consensus care bundle for the early clinical management of acute upper gastrointestinal bleeding. <i>Frontline Gastroenterology</i> , 2020, 11, 311-323.	0.9	30
41	Early Use of Fibrinogen Replacement Therapy in Postpartum Hemorrhage – A Systematic Review. <i>Transfusion Medicine Reviews</i> , 2020, 34, 101-107.	0.9	22
42	Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. <i>The Cochrane Library</i> , 2020, 2020, CD012643.	1.5	18
43	Interventions for preventing silent cerebral infarcts in people with sickle cell disease. <i>The Cochrane Library</i> , 2020, 2020, CD012389.	1.5	6
44	Convalescent plasma for COVID –19: Back to the future. <i>Transfusion Medicine</i> , 2020, 30, 174-176.	0.5	13
45	How well does your massive transfusion protocol perform? A scoping review of quality indicators. <i>Blood Transfusion</i> , 2020, 18, 423-433.	0.3	6
46	Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial). <i>Transfusion Medicine</i> , 2019, 29, 146-148.	0.5	6
47	The TREAT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial. <i>Trials</i> , 2019, 20, 592.	0.7	20
48	Donor medicine: giving it all. <i>Transfusion Medicine</i> , 2019, 29, 3-5.	0.5	0
49	Platelet transfusion thresholds in premature neonates (PlaNeT – 2 trial). <i>Transfusion Medicine</i> , 2019, 29, 20-22.	0.5	4
50	Six-month outcomes after restrictive or liberal transfusion for cardiac surgery (TRICS III trial). <i>Transfusion Medicine</i> , 2019, 29, 77-79.	0.5	8
51	Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. <i>The Cochrane Library</i> , 2019, 9, CD012643.	1.5	12
52	Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. <i>The Cochrane Library</i> , 2019, , .	1.5	2
53	Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease. <i>The Cochrane Library</i> , 2019, 2019, .	1.5	4
54	Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non-cardiac surgery or invasive procedures. <i>The Cochrane Library</i> , 2019, 2019, CD012745.	1.5	8

#	ARTICLE	IF	CITATIONS
55	National comparative audit of red blood cell transfusion practice in hospices: Recommendations for palliative care practice. <i>Palliative Medicine</i> , 2019, 33, 102-108.	1.3	17
56	Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction. <i>The Cochrane Library</i> , 2018, 2018, CD005341.	1.5	75
57	A multicentred study to validate a consensus bleeding assessment tool developed by the biomedical excellence for safer transfusion collaborative for use in patients with haematological malignancy. <i>Vox Sanguinis</i> , 2018, 113, 251-259.	0.7	7
58	Pathogen-Reduced Platelets for the Prevention of Bleeding in People of Any Age. <i>JAMA Oncology</i> , 2018, 4, 571.	3.4	13
59	Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia. <i>The Cochrane Library</i> , 2018, 2018, CD011980.	1.5	17
60	Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders. <i>The Cochrane Library</i> , 2018, 5, CD012342.	1.5	8
61	Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews. <i>The Cochrane Library</i> , 2018, 2018, CD012082.	1.5	10
62	An introduction to overviews of reviews: planning a relevant research question and objective for an overview. <i>Systematic Reviews</i> , 2018, 7, 39.	2.5	199
63	Patient blood management – a renaissance of transfusion medicine. <i>Transfusion Medicine</i> , 2018, 28, 85-88.	0.5	0
64	Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. <i>The Cochrane Library</i> , 2018, 2018, CD012349.	1.5	16
65	Prophylactic platelet transfusions prior to surgery for people with a low platelet count. <i>The Cochrane Library</i> , 2018, 2018, CD012779.	1.5	18
66	Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. <i>The Cochrane Library</i> , 2017, 1, CD003146.	1.5	17
67	Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. <i>The Cochrane Library</i> , 2017, 2017, CD011305.	1.5	20
68	Computerised decision support systems to promote appropriate use of blood products. <i>The Cochrane Library</i> , 2017, 2017, .	1.5	3
69	Interventions for preventing silent cerebral infarcts in people with sickle cell disease. <i>The Cochrane Library</i> , 2017, 5, CD012389.	1.5	13
70	Interim PET for prognosis in adults with Hodgkin lymphoma: a prognostic factor exemplar review. <i>The Cochrane Library</i> , 2017, , .	1.5	3
71	Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 263-272.	1.9	99
72	Guidelines for the use of platelet transfusions. <i>British Journal of Haematology</i> , 2017, 176, 365-394.	1.2	354

#	ARTICLE	IF	CITATIONS
73	Prophylactic platelet transfusions prior to surgery for people with a low platelet count. The Cochrane Library, 2017, 2017, .	1.5	22
74	Plasma transfusions prior to lumbar punctures and epidural catheters for people with abnormal coagulation. The Cochrane Library, 2017, 2017, CD012497.	1.5	2
75	Blood transfusion strategies in elderly patients. Lancet Haematology, the, 2017, 4, e453-e454.	2.2	11
76	Desmopressin use for minimising perioperative blood transfusion. The Cochrane Library, 2017, 2017, CD001884.	1.5	35
77	Interventions for chronic kidney disease in people with sickle cell disease. The Cochrane Library, 2017, 2017, CD012380.	1.5	9
78	Pathogen-reduced platelets for the prevention of bleeding. The Cochrane Library, 2017, 2017, CD009072.	1.5	66
79	Prophylactic plasma transfusion for patients undergoing non-cardiac surgery. The Cochrane Library, 2017, 2017, .	1.5	2
80	Effect of restrictive versus liberal red cell transfusion strategies on haemostasis: systematic review and meta-analysis. Thrombosis and Haemostasis, 2017, 117, 889-898.	1.8	11
81	Selecting and implementing overview methods: implications from five exemplar overviews. Systematic Reviews, 2017, 6, 145.	2.5	90
82	Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction. The Cochrane Library, 2016, 4, CD005339.	1.5	35
83	Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. The Cochrane Library, 2016, 2016, CD009733.	1.5	43
84	Interventions for chronic kidney disease in people with sickle cell disease. , 2016, 2016, .		4
85	Interventions for preventing silent cerebral infarcts in people with sickle cell disease. , 2016, 2016, .		6
86	Platelet Transfusions in Patients with Hypoproliferative Thrombocytopenia. Hematology/Oncology Clinics of North America, 2016, 30, 541-560.	0.9	5
87	Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews. The Cochrane Library, 2016, 2016, .	1.5	19
88	Plasma transfusions prior to insertion of central lines for people with abnormal coagulation. The Cochrane Library, 2016, 9, CD011756.	1.5	6
89	Thrombocytopenia and platelet transfusion. , 2016, , 235-244.		0
90	Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders. The Cochrane Library, 2016, 2016, .	1.5	2

#	ARTICLE	IF	CITATIONS
91	Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. The Cochrane Library, 2016, 2016, .	1.5	14
92	Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with thrombocytopenia due to chronic bone marrow failure: a network meta-analysis and systematic review. , 2016, 2016, .		15
93	Do all patients with haematological malignancies need prophylactic platelets? No. ISBT Science Series, 2016, 11, 178-181.	1.1	0
94	Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation. The Cochrane Library, 2016, 2016, CD010982.	1.5	16
95	Alternatives to allogeneic platelet transfusion. British Journal of Haematology, 2016, 175, 381-392.	1.2	35
96	An update on indications for platelet transfusion. ISBT Science Series, 2016, 11, 170-176.	1.1	1
97	Different Platelet Count Thresholds to Guide Use of Prophylactic Platelet Transfusions for Patients With Hematological Disorders After Myelosuppressive Chemotherapy or Stem Cell Transplantation. JAMA Oncology, 2016, 2, 1091.	3.4	14
98	Prognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta-analysis. The Cochrane Library, 2016, , .	1.5	5
99	Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease. The Cochrane Library, 2016, , CD008360.	1.5	9
100	Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia. The Cochrane Library, 2016, , CD011980.	1.5	14
101	Preoperative blood transfusions for sickle cell disease. The Cochrane Library, 2016, 4, CD003149.	1.5	20
102	Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders. , 2015, 3, .		14
103	Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica, 2015, 100, 740-747.	1.7	61
104	Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. The Cochrane Library, 2015, , CD010983.	1.5	31
105	Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia. , 2015, 2015, .		14
106	Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders. The Cochrane Library, 2015, , CD011577.	1.5	12
107	Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. The Cochrane Library, 2015, 2015, CD010984.	1.5	14
108	Platelet refractoriness – practical approaches and ongoing dilemmas in patient management. British Journal of Haematology, 2015, 171, 297-305.	1.2	185

#	ARTICLE	IF	CITATIONS
109	Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia. , 2015, 2015, .		4
110	Plasma transfusions prior to insertion of central lines for patients with abnormal coagulation. , 2015, 2015, .		2
111	Intracranial haemorrhage in thrombocytopenic haematology patientsâ€™a nested caseâ€™control study: the InCiTe study protocol. BMJ Open, 2014, 4, e004199.	0.8	15
112	Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. , 2014, , .		6
113	Why has demand for platelet components increased? A review. Transfusion Medicine, 2014, 24, 260-268.	0.5	65
114	Prophylactic platelet transfusions in patients with blood malignancies: cost analysis of a randomized trial. Transfusion, 2014, 54, 2394-2403.	0.8	10
115	Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignanciesâ€™The <scp>ATHENA</scp> study. British Journal of Haematology, 2014, 166, 581-591.	1.2	41
116	Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial (CME). Transfusion, 2014, 54, 2385-2393.	0.8	54
117	Does bleeding affect patientâ€™reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review. Transfusion, 2014, 54, 1166-1179.	0.8	15
118	Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. , 2014, , .		4
119	A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. , 2014, , .		4
120	Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation. , 2014, , .		5
121	Risk Factors for Bleeding: A Modelling Analysis of the TOPPS Randomized Controlled Trial of Prophylactic Platelet Transfusion. Blood, 2014, 124, 1551-1551.	0.6	6
122	Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. , 2013, , CD009733.		32
123	A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers. New England Journal of Medicine, 2013, 368, 1771-1780.	13.9	384
124	The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion, 2013, 53, 1531-1543.	0.8	46
125	Clinical trials on platelets: recent studies and what next?. ISBT Science Series, 2013, 8, 119-121.	1.1	0
126	Pathogen-reduced platelets for the prevention of bleeding. , 2013, , CD009072.		36

#	ARTICLE	IF	CITATIONS
127	Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. The Cochrane Library, 2012, , CD004269.	1.5	66
128	Platelet transfusions in haematology patients: are we using them appropriately?. Vox Sanguinis, 2012, 103, 284-293.	0.7	78
129	The Effect of a No-Prophylactic Versus Prophylactic Platelet Transfusion Strategy On Bleeding in Patients with Hematological Malignancies and Severe Thrombocytopenia (TOPPS trial). A Randomized Controlled, Non-Inferiority Trial. Blood, 2012, 120, 1-1.	0.6	26
130	Anti-Fibrinolytics (lysine analogues) for the Prevention of Bleeding in Patients with Hematological Disorders: A Systematic Review. Blood, 2012, 120, 3427-3427.	0.6	0
131	How to further develop the evidence base for transfusion medicine. Blood Transfusion, 2012, 10, 436-9.	0.3	1
132	Platelet transfusions for patients with haematological malignancies: who needs them?. British Journal of Haematology, 2011, 154, 425-440.	1.2	53
133	Prophylactic platelet transfusions. Current Opinion in Hematology, 2010, 17, 411-417.	1.2	16
134	Desmopressin use for minimising perioperative allogeneic blood transfusion. , 2004, , CD001884.		71
135	Recurrent thrombo-embolic episodes: the association of cholangiocarcinoma with antiphospholipid syndrome. Postgraduate Medical Journal, 1999, 75, 45-46.	0.9	11
136	Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation of hip, pelvic and long bone fractures: a systematic review and network meta-analysis. The Cochrane Library, 0, , .	1.5	3
137	Pharmacological interventions for the prevention of bleeding in people undergoing elective hip or knee surgery: a systematic review and network meta-analysis. The Cochrane Library, 0, , .	1.5	6
138	Drugs to reduce bleeding and transfusion in adults undergoing cardiac surgery: a systematic review and network meta-analysis. The Cochrane Library, 0, , .	1.5	3
139	Interventions for reducing red blood cell transfusion in adults undergoing hip fracture surgery: an overview of systematic reviews. The Cochrane Library, 0, , .	1.5	1
140	SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. The Cochrane Library, 0, , .	1.5	16
141	Convalescent plasma and hyperimmune immunoglobulin to prevent infection with SARS-CoV-2. The Cochrane Library, 0, , .	1.5	4
142	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. The Cochrane Library, 0, , .	1.5	2
143	Insights from developing and evaluating the <scp>NHS</scp> blood choices transfusion app to support junior and middleâ€ grade doctor decision making against guidelines. Transfusion Medicine, 0, , .	0.5	1
144	Assessing efficacy and safety of replacement fluids in therapeutic plasma exchange: A systematic scoping review of outcome measures used. Journal of Clinical Apheresis, 0, , .	0.7	3